Recently, the discovery of X-C Motif Chemokine Receptor 1 (XCR1) as a specific and conserved marker of cross-presenting DC [32] has allowed for the specific targeting of these subsets as a strategy to direct productive anti-tumor immunity [33,34,35]. This evidence concerns the gene XCR1 and neoplasm.